Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Hand-Hygiene Compliance is Low Amongst Emergency Medical Workers

Studies show paramedic workers ignored World Health Organization guidelines when soap and water or antiseptic rub was needed. 1 The University of Southern Denmark in Odense studied 77 paramedics in Finland, Sweden, Denmark, and Australia as they treated 87 patients. The study found that hand hygiene compliance among EMS providers is “remarkably low,” with an “over-reliance” on…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Studies show paramedic workers ignored World Health Organization guidelines when soap and water or antiseptic rub was needed. 1 The University of Southern Denmark in Odense studied 77 paramedics in Finland, Sweden, Denmark, and Australia as they treated 87 patients. The study found that hand hygiene compliance among EMS providers is “remarkably low,” with an “over-reliance” on gloves and a “tendency toward self-protection instead of patient protection.”2 They found that only 3% of emergency medical personnel used either hand-wash or hand sanitizers before patient contact. Gloves were worn in 54% of all hand hygiene indications. Researchers said that while the paramedics complied with basic hygiene at a high rate, many ignored World Health Organization guidelines in instances where soap and water or antiseptic rub was needed.

A Worldwide Problem

Hand hygiene compliance isn’t just a problem that’s isolated to Europe either. A study published in the American Journal of Infection Control (AJIC), tracked hygienic practices at hospitals in the United States and found disturbingly similar results.3 In this study, all participants believed they were fully compliant, and yet, less than half used proper hand-washing techniques, and just over a third wore gloves. And unfortunately, far too many of those in the study believed gloves were enough protection. However, researchers were keen to point out that proper hand-washing and gloves are both crucial to preventing infections spreading from either party. According to the AJIC study, “Hand hygiene and glove use are highly intertwined in clinical practice and should be considered jointly in infection prevention improvement efforts.”

Knowing the Proper Procedure

When 1 in 31 hospital patients has an infection resulting from the healthcare they received, increased vigilance must be taken to ensure that EMS providers are complying with CDC guidelines for hand hygiene.4 The CDC recommends washing your hands with either alcohol-based sanitizers or antiseptic soaps both before and after eating, having contact with a patient’s skin or fluids, and touching inanimate surfaces near the patient. Additionally, hand-washing is vital after using the restroom, and especially after taking off gloves. Gloves are critical to proper hand hygiene in patient care, but all hygienic measures must be taken to ensure across-the-board safety.

AliMed has a wide selection of products to help prevent infection with solutions for every setting. To learn more about our infection control products visit https://www.alimed.com/infection-control/

References

  1. Vikke HS, Vittinghus S, Giebner M, et al Compliance with hand hygiene in emergency medical services: an international observational study Emerg Med J 2019;36:171-175.
  2. Vikke HS, Vittinghus S, Giebner M, et al Compliance with hand hygiene in emergency medical services: an international observational study Emerg Med J 2019;36:171-175.
  3. https://www.ajicjournal.org/article/S0196-6553(18)31107-6/fulltext
  4. https://www.cdc.gov/handhygiene/index.html

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512